FDA Approves Unknown Drug — ABBVIE

U.S. regulators approved AbbVie’s **Humira** (adalimumab), the biopharmaceutical giant’s best-selling therapy, bringing the blockbuster drug to market as a generic for the first time. This pivotal event sets the stage for a dramatic shift in the pharmaceutical landscape, slashing AbbVie’s revenue and igniting long-awaited competition from rival manufacturers.